Aaron F. Baldwin
Research Subjects
Aaron F. Baldwin has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Christophe Allais
Chemical Research and Development
6 shared publications Chintelle James
Pfizer Chemical Research and Development, Pfizer Worldwide Research and Development
5 shared publicationsGerald A. Weisenburger
Pfizer Chemical Research and Development, Pfizer Worldwide Research and Development
5 shared publicationsNga M. Do
Chemical Research & Development, Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
5 shared publicationsR. Matthew Weekly
Pfizer Chemical Research and Development, Pfizer Worldwide Research and Development
5 shared publications- Taegyo Lee
Chemical Research and Development, Pfizer Worldwide Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States
5 shared publications
Latest Publications
- 6 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5562-5571
Crystallization Behavior of Amorphous Solid DispersionsRole of Nucleation and Nucleation Density
The Tnose for nucleation (i.e., the temperature of the maximum nucleation rate without any crystal growth) of flurbiprofen-polyvinylpyrrolidone amorphous solid dispersions (ASDs) was determined using the time−temperature−transformation (TTT) diagram. Varying levels of nucleation were induced in ASDs by annealing for different time periods at Tnose for nucleation. Synchrotron X-ray diffractometry was utilized for real-time monitoring of the crystallization behavior upon wetting the ASDs with water. An increase in the nucleation density shortened the lag time and also accelerated drug crystallization. Williamson−Hall analysis of the X-ray data revealed a progressive reduction in the lattice strain (increased lattice order) of the crystallizing phase with increasing contact time with water. From performance perspectives, actualizing the solubility advantage of the amorphous drug necessitates retaining supersaturation for a sufficiently long period to allow absorption from the gastrointestinal tract. However, the presence of nuclei, by facilitating crystallization, can negate the solubility and the consequent bioavailability advantage of ASDs. A systematic framework for evaluating the “health” of ASDs was established, highlighting that the absence of nuclei would be an essential attribute of robust ASDs.
- 6 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5562-5571
Crystallization Behavior of Amorphous Solid DispersionsRole of Nucleation and Nucleation Density
The Tnose for nucleation (i.e., the temperature of the maximum nucleation rate without any crystal growth) of flurbiprofen-polyvinylpyrrolidone amorphous solid dispersions (ASDs) was determined using the time−temperature−transformation (TTT) diagram. Varying levels of nucleation were induced in ASDs by annealing for different time periods at Tnose for nucleation. Synchrotron X-ray diffractometry was utilized for real-time monitoring of the crystallization behavior upon wetting the ASDs with water. An increase in the nucleation density shortened the lag time and also accelerated drug crystallization. Williamson−Hall analysis of the X-ray data revealed a progressive reduction in the lattice strain (increased lattice order) of the crystallizing phase with increasing contact time with water. From performance perspectives, actualizing the solubility advantage of the amorphous drug necessitates retaining supersaturation for a sufficiently long period to allow absorption from the gastrointestinal tract. However, the presence of nuclei, by facilitating crystallization, can negate the solubility and the consequent bioavailability advantage of ASDs. A systematic framework for evaluating the “health” of ASDs was established, highlighting that the absence of nuclei would be an essential attribute of robust ASDs.
- 11 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (10) , 2637-2648
Early Development of Ibuzatrelvir: Navigating Polymorph and Crystallization Challenges in a Protecting Group-Free Direct Amidation and Amidation-Dehydration Sequence
Ibuzatrelvir is an orally bioavailable, next-generation clinical candidate developed for the treatment of COVID-19 infections. It was identified during the pandemic, prior to the approval of PAXLOVID, and displays a more favorable pharmacokinetic profile than nirmatrelvir. Consequently, the initial development of ibuzatrelvir proceeded under highly accelerated timelines. This report details the optimization of the end-stage synthesis sequence and its advancement throughout the initial clinical production campaigns. The study highlights an efficient protecting group-free amidation of tert-leucine and describes a complex isolation process following a telescoped amidation-dehydration cascade leading to ibuzatrelvir with a 30% increase in yield. The finalized synthetic route was successfully scaled up, enabling the manufacture of several hundred kilograms to support clinical research initiatives.
- 11 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (10) , 2637-2648
Early Development of Ibuzatrelvir: Navigating Polymorph and Crystallization Challenges in a Protecting Group-Free Direct Amidation and Amidation-Dehydration Sequence
Ibuzatrelvir is an orally bioavailable, next-generation clinical candidate developed for the treatment of COVID-19 infections. It was identified during the pandemic, prior to the approval of PAXLOVID, and displays a more favorable pharmacokinetic profile than nirmatrelvir. Consequently, the initial development of ibuzatrelvir proceeded under highly accelerated timelines. This report details the optimization of the end-stage synthesis sequence and its advancement throughout the initial clinical production campaigns. The study highlights an efficient protecting group-free amidation of tert-leucine and describes a complex isolation process following a telescoped amidation-dehydration cascade leading to ibuzatrelvir with a 30% increase in yield. The finalized synthetic route was successfully scaled up, enabling the manufacture of several hundred kilograms to support clinical research initiatives.
- 11 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (10) , 2625-2636
Late-Stage Kinetic Hydrolysis to Prepare an Advanced Intermediate for Ibuzatrelvir
Ibuzatrelvir is a second-generation, orally administered protease inhibitor of the SARS-CoV-2 MPro virus that is currently being evaluated for the treatment of Covid-19. The molecule contains a substituted trans-trifluoromethylproline fragment that, although it had been the focus of previous synthetic efforts, was still identified as a target for improvement. Herein, we describe a route featuring the late-stage introduction of a stereocenter via a mechanistically distinct diastereoselective kinetic hydrolysis. This bold strategy has resulted in significant efficiency, environmental, and process dividends, underscoring the impact of a continuous-improvement approach to chemical development.
- 11 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (10) , 2625-2636
Late-Stage Kinetic Hydrolysis to Prepare an Advanced Intermediate for Ibuzatrelvir
Ibuzatrelvir is a second-generation, orally administered protease inhibitor of the SARS-CoV-2 MPro virus that is currently being evaluated for the treatment of Covid-19. The molecule contains a substituted trans-trifluoromethylproline fragment that, although it had been the focus of previous synthetic efforts, was still identified as a target for improvement. Herein, we describe a route featuring the late-stage introduction of a stereocenter via a mechanistically distinct diastereoselective kinetic hydrolysis. This bold strategy has resulted in significant efficiency, environmental, and process dividends, underscoring the impact of a continuous-improvement approach to chemical development.
- 25 February 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (3) , 753-760
Development of a Flow Process to tert -Butyl 4-(6-Chloropyridin-2-yl)piperidine-1-carboxylate
- 25 February 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (3) , 753-760
Development of a Flow Process to tert -Butyl 4-(6-Chloropyridin-2-yl)piperidine-1-carboxylate
- 1 January 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (1) , 198-203
Synthesis of 3-Fluoro-4-(hydroxymethyl)benzonitrile via Photobromination: Enabling Manufacturing Pathways for Danuglipron Starting Materials
- 1 January 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (1) , 198-203
Synthesis of 3-Fluoro-4-(hydroxymethyl)benzonitrile via Photobromination: Enabling Manufacturing Pathways for Danuglipron Starting Materials
- 8 November 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (12) , 4444-4454
Building and Evolving a Chiral Control Strategy for Accelerated COVID Programs
- 8 November 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (12) , 4444-4454
Building and Evolving a Chiral Control Strategy for Accelerated COVID Programs
- 4 December 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2260-2270
Synthesis of Nirmatrelvir: Development of a Scalable Cobalt-Catalyzed Cyclopropanation for Manufacture of the Bicyclic [3.1.0]Proline-Building Block
- 4 December 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2260-2270
Synthesis of Nirmatrelvir: Development of a Scalable Cobalt-Catalyzed Cyclopropanation for Manufacture of the Bicyclic [3.1.0]Proline-Building Block
- 25 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2240-2249
Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment
- 25 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2240-2249
Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment
- 17 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2250-2259
Synthesis of Nirmatrelvir: Design and Optimization of an Efficient Telescoped Amidation–Dehydration Sequence
- 17 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (12) , 2250-2259
Synthesis of Nirmatrelvir: Design and Optimization of an Efficient Telescoped Amidation–Dehydration Sequence